CCN2 and Duchenne muscular dystrophy: These findings led to the development of pamrevlumab, an anti-CTGF human monoclonal antibody that is being tested in a phase-II clinical trial in patients with Duchenne Muscular Dystrophy (DMD) (https://www.clinicaltrials.gov/ct2/show/NCT02606136).